Other Clinical Trial - TCR-Redirected T Cell Treatment in Patients With

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04851119` - Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors	Phase 1/Phase 2
Active, not recruiting	`NCT02143401` - Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors	Phase 1
Active, not recruiting	`NCT04514484` - Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV	Phase 1
Completed	`NCT02728219` - Comparison of Treatment of Recurrent HCC With Repeat Hepatectomy,and TACE With AFP Conversion	N/A
Active, not recruiting	`NCT02867592` - Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors	Phase 2
Completed	`NCT01522820` - Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors	Phase 1
Recruiting	`NCT03609268` - Stereotactic Body Radiotherapy and Microwave Ablation for Recurrent Small Hepatocellular Carcinoma	N/A
Completed	`NCT02613156` - Efficacy Analysis of Complete Laparoscopic Resection of Recurrent Hepatocellular Carcinoma	N/A
Recruiting	`NCT02719782` - A Study of TCR-Redirected T Cell Infusion in Subject With Recurrent HBV-related HCC Post Liver Transplantation	Phase 1
Recruiting	`NCT04800497` - The Role Of Circulating Tumor Cells As Markers Of Advanced Disease And Prognosis In HCC
Active, not recruiting	`NCT03257761` - Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer	Phase 1
Terminated	`NCT02762266` - Transarterial Chemoembolization Compared With Stereotactic Body Radiation Therapy or Stereotactic Ablative Radiation Therapy in Treating Patients With Residual or Recurrent Liver Cancer Undergone Initial Transarterial Chemoembolization	Phase 3
Active, not recruiting	`NCT03655002` - IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer	Phase 1
Withdrawn	`NCT01318200` - Transarterial Chemoembolization (TACE) vs. CyberKnife for Recurrent Hepatocellular Carcinoma (HCC)	Phase 3
Completed	`NCT01015833` - Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer	Phase 3
Recruiting	`NCT04663035` - Ablation Plus Tislelizumab Versus Ablation Alone for Intrahepatic Recurrent Early Stage HCC	Phase 2
Withdrawn	`NCT05327738` - Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma	Phase 2
Recruiting	`NCT04615143` - Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC	Phase 2
Active, not recruiting	`NCT04805788` - Stereotactic Body Proton Radiotherapy for the Treatment of Liver Cancer	Phase 2
Withdrawn	`NCT03634683` - A Study of LioCyx in Patient With Recurrent HBV-related HCC Post Liver Transplantation	Phase 1/Phase 2

NCT number	NCT04677088
Study type	Interventional
Source	First Affiliated Hospital, Sun Yat-Sen University
Contact
Status	Active, not recruiting
Phase	Phase 1
Start date	March 29, 2018
Completion date	December 2021

TCR-Redirected T Cell Treatment in Patients With Recurrent HBV-related Hepatocellular Carcinoma Post Liver Transplantation

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms